Opioid Induced Constipation (OIC) Drug Market Report

Europe Opioid Induced Constipation (OIC) Drug Market Size, Status and Forecast 2014-2026

  • POSTDATE：Feb 03, 2020
  • PAGES：166
  • REPORT CODE：GMM458995
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The Opioid Induced Constipation (OIC) Drug market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 6.0% during the forecast period. Focusing on the Europe market, this report analyzes the specific consumption structure, such as types and end users. In order to present the status of the circulation of this product in different Europe countries, this report covers top export and import countries to confirm the potential markets. Leading countries such as Germany, UK, France, Italy, Spain, Poland, Russia, Switzerland, Turkey, Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden), Benelux (Belgium, Netherlands, and Luxembourg), Baltic States (Estonia, Latvia, and Lithuania) and other countries, the market status and consumption potential of these countries are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

    The Snapshot of Europe Opioid Induced Constipation (OIC) Drug Market Segmentations:

    By Player:

    • Allergan

    • Daewoong Pharmaceutical

    • Cosmo Pharmaceuticals SA

    • Shionogi &

    • S.L.A. Pharma

    • Progenics Pharmaceuticals

    • C.B. Fleet Company

    • Nektar Therapeutics

    • Theravance Biopharma

    • Ironwood Pharmaceuticals

    • SLA Pharma

    • Sucampo Pharmaceuticals

    • Daiichi Sankyo Co

    • Pfizer

    • Takeda Pharmaceutical Company Limited

    • Mundipharma International Limited

    • Purdue Pharma

    • Valeant Pharmaceuticals International

    By Type:

    • Lubiprostone

    • Methyl Naltrexone Bromide

    • Naldemedine

    • Alvimopan

    • Other

    By End-User:

    • Hospital Pharmacies

    • Retail Pharmacies

    • Online Pharmacies

    By Region:

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Poland

    • Russia

    • Switzerland

    • Turkey

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

      • Denmark

      • Finland

      • Norway

      • Sweden

      • Iceland

    • Benelux (Belgium, Netherlands, and Luxembourg)

      • Belgium

      • Netherlands

      • Luxembourg

    • Baltic States (Estonia, Latvia, and Lithuania)

      • Estonia

      • Latvia

      • Lithuania

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Opioid Induced Constipation (OIC) Drug Market

    • 1.3 Market Segment by Type

    • 1.3.1 Europe Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Lubiprostone from 2014 to 2026

    • 1.3.2 Europe Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Methyl Naltrexone Bromide from 2014 to 2026

    • 1.3.3 Europe Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Naldemedine from 2014 to 2026

    • 1.3.4 Europe Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Alvimopan from 2014 to 2026

    • 1.3.5 Europe Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Other from 2014 to 2026

    • 1.4 Market Segment by Application

    • 1.4.1 Europe Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Hospital Pharmacies from 2014 to 2026

    • 1.4.2 Europe Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Retail Pharmacies from 2014 to 2026

    • 1.4.3 Europe Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Online Pharmacies from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Germany Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 UK Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 France Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Italy Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Spain Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Poland Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Russia Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Switzerland Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.9 Turkey Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.11 Benelux (Belgium, Netherlands, and Luxembourg) Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.12 Baltic States (Estonia, Latvia, and Lithuania) Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of Opioid Induced Constipation (OIC) Drug Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Venders

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Opioid Induced Constipation (OIC) Drug by Major Types

      • 3.4.1 Market Size and Growth Rate of Lubiprostone

      • 3.4.2 Market Size and Growth Rate of Methyl Naltrexone Bromide

      • 3.4.3 Market Size and Growth Rate of Naldemedine

      • 3.4.4 Market Size and Growth Rate of Alvimopan

      • 3.4.5 Market Size and Growth Rate of Other

    4 Segmentation of Opioid Induced Constipation (OIC) Drug Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Opioid Induced Constipation (OIC) Drug by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Opioid Induced Constipation (OIC) Drug for Hospital Pharmacies

      • 4.4.2 Market Size and Growth Rate of Opioid Induced Constipation (OIC) Drug for Retail Pharmacies

      • 4.4.3 Market Size and Growth Rate of Opioid Induced Constipation (OIC) Drug for Online Pharmacies

    5 Market Analysis by Major Regions

    • 5.1 Europe Opioid Induced Constipation (OIC) Drug Production Analysis by Top Regions

    • 5.2 Europe Opioid Induced Constipation (OIC) Drug Consumption Analysis by Top Regions

    • 5.3 Europe Opioid Induced Constipation (OIC) Drug Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 Germany Opioid Induced Constipation (OIC) Drug Production, Import, Consumption and Export Analysis

      • 5.3.2 UK Opioid Induced Constipation (OIC) Drug Production, Import, Consumption and Export Analysis

      • 5.3.3 France Opioid Induced Constipation (OIC) Drug Production, Import, Consumption and Export Analysis

      • 5.3.4 Italy Opioid Induced Constipation (OIC) Drug Production, Import, Consumption and Export Analysis

      • 5.3.5 Spain Opioid Induced Constipation (OIC) Drug Production, Import, Consumption and Export Analysis

      • 5.3.6 Poland Opioid Induced Constipation (OIC) Drug Production, Import, Consumption and Export Analysis

      • 5.3.7 Russia Opioid Induced Constipation (OIC) Drug Production, Import, Consumption and Export Analysis

      • 5.3.8 Switzerland Opioid Induced Constipation (OIC) Drug Production, Import, Consumption and Export Analysis

      • 5.3.9 Turkey Opioid Induced Constipation (OIC) Drug Production, Import, Consumption and Export Analysis

      • 5.3.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Opioid Induced Constipation (OIC) Drug Production, Import, Consumption and Export Analysis

      • 5.3.11 Benelux (Belgium, Netherlands, and Luxembourg) Opioid Induced Constipation (OIC) Drug Production, Import, Consumption and Export Analysis

      • 5.3.12 Baltic States (Estonia, Latvia, and Lithuania) Opioid Induced Constipation (OIC) Drug Production, Import, Consumption and Export Analysis

    6 Product Circulation of Opioid Induced Constipation (OIC) Drug Market among Top Countries

    • 6.1 Top 5 Export Countries in Opioid Induced Constipation (OIC) Drug Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in Opioid Induced Constipation (OIC) Drug Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in Opioid Induced Constipation (OIC) Drug Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in Opioid Induced Constipation (OIC) Drug Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in Opioid Induced Constipation (OIC) Drug Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in Opioid Induced Constipation (OIC) Drug Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. Germany Opioid Induced Constipation (OIC) Drug Landscape Analysis

    • 7.1 Germany Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major Types

    • 7.2 Germany Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major End-Users

    8. UK Opioid Induced Constipation (OIC) Drug Landscape Analysis

    • 8.1 UK Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major Types

    • 8.2 UK Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major End-Users

    9. France Opioid Induced Constipation (OIC) Drug Landscape Analysis

    • 9.1 France Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major Types

    • 9.2 France Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major End-Users

    10. Italy Opioid Induced Constipation (OIC) Drug Landscape Analysis

    • 10.1 Italy Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major Types

    • 10.2 Italy Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major End-Users

    11. Spain Opioid Induced Constipation (OIC) Drug Landscape Analysis

    • 11.1 Spain Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major Types

    • 11.2 Spain Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major End-Users

    12. Poland Opioid Induced Constipation (OIC) Drug Landscape Analysis

    • 12.1 Poland Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major Types

    • 12.2 Poland Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major End-Users

    13. Russia Opioid Induced Constipation (OIC) Drug Landscape Analysis

    • 13.1 Russia Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major Types

    • 13.2 Russia Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major End-Users

    14. Switzerland Opioid Induced Constipation (OIC) Drug Landscape Analysis

    • 14.1 Switzerland Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major Types

    • 14.2 Switzerland Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major End-Users

    15. Turkey Opioid Induced Constipation (OIC) Drug Landscape Analysis

    • 15.1 Turkey Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major Types

    • 15.2 Turkey Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major End-Users

    16. Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Opioid Induced Constipation (OIC) Drug Landscape Analysis

    • 16.1 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major Types

    • 16.2 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major End-Users

    • 16.3 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Opioid Induced Constipation (OIC) Drug Landscape Analysis by Top Countries

      • 16.3.1 Denmark Opioid Induced Constipation (OIC) Drug Market Volume and Growth Rate

      • 16.3.2 Finland Opioid Induced Constipation (OIC) Drug Market Volume and Growth Rate

      • 16.3.3 Norway Opioid Induced Constipation (OIC) Drug Market Volume and Growth Rate

      • 16.3.4 Sweden Opioid Induced Constipation (OIC) Drug Market Volume and Growth Rate

      • 16.3.6 Iceland Opioid Induced Constipation (OIC) Drug Market Volume and Growth Rate

    17 Benelux (Belgium, Netherlands, and Luxembourg) Opioid Induced Constipation (OIC) Drug Landscape Analysis

    • 17.1 Benelux (Belgium, Netherlands, and Luxembourg) Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major Types

    • 17.2 Benelux (Belgium, Netherlands, and Luxembourg) Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major End-Users

    • 17.3 Benelux (Belgium, Netherlands, and Luxembourg) Opioid Induced Constipation (OIC) Drug Landscape Analysis by Top Countries

      • 17.3.1 Belgium Opioid Induced Constipation (OIC) Drug Market Volume and Growth Rate

      • 17.3.2 Netherlands Opioid Induced Constipation (OIC) Drug Market Volume and Growth Rate

      • 17.3.3 Luxembourg Opioid Induced Constipation (OIC) Drug Market Volume and Growth Rate

    18 Baltic States (Estonia, Latvia, and Lithuania) Opioid Induced Constipation (OIC) Drug Landscape Analysis

    • 18.1 Baltic States (Estonia, Latvia, and Lithuania) Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major Types

    • 18.2 Baltic States (Estonia, Latvia, and Lithuania) Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major End-Users

    • 18.3 Baltic States (Estonia, Latvia, and Lithuania) Opioid Induced Constipation (OIC) Drug Landscape Analysis by Top Countries

      • 18.3.1 Estonia Opioid Induced Constipation (OIC) Drug Market Volume and Growth Rate

      • 18.3.2 Latvia Opioid Induced Constipation (OIC) Drug Market Volume and Growth Rate

      • 18.3.3 Lithuania Opioid Induced Constipation (OIC) Drug Market Volume and Growth Rate

    19 Major Players Profiles

    • 19.1 Allergan

      • 19.1.1 Allergan Company Profile and Development Status

      • 19.1.2 Market Performance

      • 19.1.3 Product and Service Introduction

    • 19.2 Daewoong Pharmaceutical

      • 19.2.1 Daewoong Pharmaceutical Company Profile and Development Status

      • 19.2.2 Market Performance

      • 19.2.3 Product and Service Introduction

    • 19.3 Cosmo Pharmaceuticals SA

      • 19.3.1 Cosmo Pharmaceuticals SA Company Profile and Development Status

      • 19.3.2 Market Performance

      • 19.3.3 Product and Service Introduction

    • 19.4 Shionogi &

      • 19.4.1 Shionogi & Company Profile and Development Status

      • 19.4.2 Market Performance

      • 19.4.3 Product and Service Introduction

    • 19.5 S.L.A. Pharma

      • 19.5.1 S.L.A. Pharma Company Profile and Development Status

      • 19.5.2 Market Performance

      • 19.5.3 Product and Service Introduction

    • 19.6 Progenics Pharmaceuticals

      • 19.6.1 Progenics Pharmaceuticals Company Profile and Development Status

      • 19.6.2 Market Performance

      • 19.6.3 Product and Service Introduction

    • 19.7 C.B. Fleet Company

      • 19.7.1 C.B. Fleet Company Company Profile and Development Status

      • 19.7.2 Market Performance

      • 19.7.3 Product and Service Introduction

    • 19.8 Nektar Therapeutics

      • 19.8.1 Nektar Therapeutics Company Profile and Development Status

      • 19.8.2 Market Performance

      • 19.8.3 Product and Service Introduction

    • 19.9 Theravance Biopharma

      • 19.9.1 Theravance Biopharma Company Profile and Development Status

      • 19.9.2 Market Performance

      • 19.9.3 Product and Service Introduction

    • 19.10 Ironwood Pharmaceuticals

      • 19.10.1 Ironwood Pharmaceuticals Company Profile and Development Status

      • 19.10.2 Market Performance

      • 19.10.3 Product and Service Introduction

    • 19.11 SLA Pharma

      • 19.11.1 SLA Pharma Company Profile and Development Status

      • 19.11.2 Market Performance

      • 19.11.3 Product and Service Introduction

    • 19.12 Sucampo Pharmaceuticals

      • 19.12.1 Sucampo Pharmaceuticals Company Profile and Development Status

      • 19.12.2 Market Performance

      • 19.12.3 Product and Service Introduction

    • 19.13 Daiichi Sankyo Co

      • 19.13.1 Daiichi Sankyo Co Company Profile and Development Status

      • 19.13.2 Market Performance

      • 19.13.3 Product and Service Introduction

    • 19.14 Pfizer

      • 19.14.1 Pfizer Company Profile and Development Status

      • 19.14.2 Market Performance

      • 19.14.3 Product and Service Introduction

    • 19.15 Takeda Pharmaceutical Company Limited

      • 19.15.1 Takeda Pharmaceutical Company Limited Company Profile and Development Status

      • 19.15.2 Market Performance

      • 19.15.3 Product and Service Introduction

    • 19.16 Mundipharma International Limited

      • 19.16.1 Mundipharma International Limited Company Profile and Development Status

      • 19.16.2 Market Performance

      • 19.16.3 Product and Service Introduction

    • 19.17 Purdue Pharma

      • 19.17.1 Purdue Pharma Company Profile and Development Status

      • 19.17.2 Market Performance

      • 19.17.3 Product and Service Introduction

    • 19.18 Valeant Pharmaceuticals International

      • 19.18.1 Valeant Pharmaceuticals International Company Profile and Development Status

      • 19.18.2 Market Performance

      • 19.18.3 Product and Service Introduction

    The List of Tables and Figures (Totals 66 Figures and 131 Tables)

    • Figure Product Picture

    • Figure Europe Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Lubiprostone from 2014 to 2026

    • Figure Europe Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Methyl Naltrexone Bromide from 2014 to 2026

    • Figure Europe Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Naldemedine from 2014 to 2026

    • Figure Europe Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Alvimopan from 2014 to 2026

    • Figure Europe Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Other from 2014 to 2026

    • Figure Europe Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Hospital Pharmacies from 2014 to 2026

    • Figure Europe Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Retail Pharmacies from 2014 to 2026

    • Figure Europe Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Online Pharmacies from 2014 to 2026

    • Figure Germany Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure UK Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure France Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Italy Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Spain Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Poland Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Russia Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Switzerland Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Canada Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Denmark Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Finland Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Norway Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Sweden Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Iceland Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Benelux (Belgium, Netherlands, and Luxembourg) Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Netherlands Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Luxembourg Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Baltic States (Estonia, Latvia, and Lithuania) Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Estonia Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Latvia Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Lithuania Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Opioid Induced Constipation (OIC) Drug Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Opioid Induced Constipation (OIC) Drug

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Opioid Induced Constipation (OIC) Drug by Different Types from 2014 to 2026

    • Table Consumption Share of Opioid Induced Constipation (OIC) Drug by Different Types from 2014 to 2026

    • Figure Market Size and Growth Rate of Lubiprostone

    • Figure Market Size and Growth Rate of Methyl Naltrexone Bromide

    • Figure Market Size and Growth Rate of Naldemedine

    • Figure Market Size and Growth Rate of Alvimopan

    • Figure Market Size and Growth Rate of Other

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Opioid Induced Constipation (OIC) Drug by Different End-Users from 2014 to 2026

    • Table Consumption Share of Opioid Induced Constipation (OIC) Drug by Different End-Users from 2014 to 2026

    • Figure Market Size and Growth Rate of Hospital Pharmacies

    • Figure Market Size and Growth Rate of Retail Pharmacies

    • Figure Market Size and Growth Rate of Online Pharmacies

    • Table Europe Opioid Induced Constipation (OIC) Drug Production by Major Regions

    • Table Europe Opioid Induced Constipation (OIC) Drug Production Share by Major Regions

    • Figure Europe Opioid Induced Constipation (OIC) Drug Production Share by Major Countries and Regions in 2014

    • Table Europe Opioid Induced Constipation (OIC) Drug Consumption by Major Regions

    • Table Europe Opioid Induced Constipation (OIC) Drug Consumption Share by Major Regions

    • Table Germany Opioid Induced Constipation (OIC) Drug Production, Import, Consumption and Export Analysis

    • Table UK Opioid Induced Constipation (OIC) Drug Production, Import, Consumption and Export Analysis

    • Table France Opioid Induced Constipation (OIC) Drug Production, Import, Consumption and Export Analysis

    • Table Italy Opioid Induced Constipation (OIC) Drug Production, Import, Consumption and Export Analysis

    • Table Spain Opioid Induced Constipation (OIC) Drug Production, Import, Consumption and Export Analysis

    • Table Poland Opioid Induced Constipation (OIC) Drug Production, Import, Consumption and Export Analysis

    • Table Russia Opioid Induced Constipation (OIC) Drug Production, Import, Consumption and Export Analysis

    • Table Switzerland Opioid Induced Constipation (OIC) Drug Production, Import, Consumption and Export Analysis

    • Table Turkey Opioid Induced Constipation (OIC) Drug Production, Import, Consumption and Export Analysis

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Opioid Induced Constipation (OIC) Drug Production, Import, Consumption and Export Analysis

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Opioid Induced Constipation (OIC) Drug Production, Import, Consumption and Export Analysis

    • Table Baltic States (Estonia, Latvia, and Lithuania) Opioid Induced Constipation (OIC) Drug Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in Opioid Induced Constipation (OIC) Drug Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in Opioid Induced Constipation (OIC) Drug Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in Opioid Induced Constipation (OIC) Drug Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in Opioid Induced Constipation (OIC) Drug Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table Germany Opioid Induced Constipation (OIC) Drug Consumption by Types from 2014 to 2026

    • Table Germany Opioid Induced Constipation (OIC) Drug Consumption Share by Types from 2014 to 2026

    • Table Germany Opioid Induced Constipation (OIC) Drug Consumption by End-Users from 2014 to 2026

    • Table Germany Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users from 2014 to 2026

    • Table UK Opioid Induced Constipation (OIC) Drug Consumption by Types from 2014 to 2026

    • Table UK Opioid Induced Constipation (OIC) Drug Consumption Share by Types from 2014 to 2026

    • Table UK Opioid Induced Constipation (OIC) Drug Consumption by End-Users from 2014 to 2026

    • Table UK Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users from 2014 to 2026

    • Table France Opioid Induced Constipation (OIC) Drug Consumption by Types from 2014 to 2026

    • Table France Opioid Induced Constipation (OIC) Drug Consumption Share by Types from 2014 to 2026

    • Table France Opioid Induced Constipation (OIC) Drug Consumption by End-Users from 2014 to 2026

    • Table France Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users from 2014 to 2026

    • Table Italy Opioid Induced Constipation (OIC) Drug Consumption by Types from 2014 to 2026

    • Table Italy Opioid Induced Constipation (OIC) Drug Consumption Share by Types from 2014 to 2026

    • Table Italy Opioid Induced Constipation (OIC) Drug Consumption by End-Users from 2014 to 2026

    • Table Italy Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users from 2014 to 2026

    • Table Spain Opioid Induced Constipation (OIC) Drug Consumption by Types from 2014 to 2026

    • Table Spain Opioid Induced Constipation (OIC) Drug Consumption Share by Types from 2014 to 2026

    • Table Spain Opioid Induced Constipation (OIC) Drug Consumption by End-Users from 2014 to 2026

    • Table Spain Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users from 2014 to 2026

    • Table Poland Opioid Induced Constipation (OIC) Drug Consumption by Types from 2014 to 2026

    • Table Poland Opioid Induced Constipation (OIC) Drug Consumption Share by Types from 2014 to 2026

    • Table Poland Opioid Induced Constipation (OIC) Drug Consumption by End-Users from 2014 to 2026

    • Table Poland Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users from 2014 to 2026

    • Table Russia Opioid Induced Constipation (OIC) Drug Consumption by Types from 2014 to 2026

    • Table Russia Opioid Induced Constipation (OIC) Drug Consumption Share by Types from 2014 to 2026

    • Table Russia Opioid Induced Constipation (OIC) Drug Consumption by End-Users from 2014 to 2026

    • Table Russia Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users from 2014 to 2026

    • Table Switzerland Opioid Induced Constipation (OIC) Drug Consumption by Types from 2014 to 2026

    • Table Switzerland Opioid Induced Constipation (OIC) Drug Consumption Share by Types from 2014 to 2026

    • Table Switzerland Opioid Induced Constipation (OIC) Drug Consumption by End-Users from 2014 to 2026

    • Table Switzerland Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users from 2014 to 2026

    • Table Turkey Opioid Induced Constipation (OIC) Drug Consumption by Types from 2014 to 2026

    • Table Turkey Opioid Induced Constipation (OIC) Drug Consumption Share by Types from 2014 to 2026

    • Table Turkey Opioid Induced Constipation (OIC) Drug Consumption by End-Users from 2014 to 2026

    • Table Turkey Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Opioid Induced Constipation (OIC) Drug Consumption by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Opioid Induced Constipation (OIC) Drug Consumption Share by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Opioid Induced Constipation (OIC) Drug Consumption by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Opioid Induced Constipation (OIC) Drug Consumption by Major Countries from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Opioid Induced Constipation (OIC) Drug Consumption Share by Major Countries from 2014 to 2026

    • Figure Denmark Opioid Induced Constipation (OIC) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland Opioid Induced Constipation (OIC) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway Opioid Induced Constipation (OIC) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden Opioid Induced Constipation (OIC) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland Opioid Induced Constipation (OIC) Drug Market Volume and Growth Rate from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Opioid Induced Constipation (OIC) Drug Consumption by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Opioid Induced Constipation (OIC) Drug Consumption Share by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Opioid Induced Constipation (OIC) Drug Consumption by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Opioid Induced Constipation (OIC) Drug Consumption by Major Countries from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Opioid Induced Constipation (OIC) Drug Consumption Share by Major Countries from 2014 to 2026

    • Figure Belgium Opioid Induced Constipation (OIC) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands Opioid Induced Constipation (OIC) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Luxembourg Opioid Induced Constipation (OIC) Drug Market Volume and Growth Rate from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Opioid Induced Constipation (OIC) Drug Consumption by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Opioid Induced Constipation (OIC) Drug Consumption Share by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Opioid Induced Constipation (OIC) Drug Consumption by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Opioid Induced Constipation (OIC) Drug Consumption by Major Countries from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Opioid Induced Constipation (OIC) Drug Consumption Share by Major Countries from 2014 to 2026

    • Figure Estonia Opioid Induced Constipation (OIC) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Latvia Opioid Induced Constipation (OIC) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Lithuania Countries Opioid Induced Constipation (OIC) Drug Market Volume and Growth Rate from 2014 to 2026

    • Table Company Profile and Development Status of Allergan

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Allergan

    • Figure Sales and Growth Rate Analysis of Allergan

    • Figure Revenue and Market Share Analysis of Allergan

    • Table Product and Service Introduction of Allergan

    • Table Company Profile and Development Status of Daewoong Pharmaceutical

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Daewoong Pharmaceutical

    • Figure Sales and Growth Rate Analysis of Daewoong Pharmaceutical

    • Figure Revenue and Market Share Analysis of Daewoong Pharmaceutical

    • Table Product and Service Introduction of Daewoong Pharmaceutical

    • Table Company Profile and Development Status of Cosmo Pharmaceuticals SA

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Cosmo Pharmaceuticals SA

    • Figure Sales and Growth Rate Analysis of Cosmo Pharmaceuticals SA

    • Figure Revenue and Market Share Analysis of Cosmo Pharmaceuticals SA

    • Table Product and Service Introduction of Cosmo Pharmaceuticals SA

    • Table Company Profile and Development Status of Shionogi &

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Shionogi &

    • Figure Sales and Growth Rate Analysis of Shionogi &

    • Figure Revenue and Market Share Analysis of Shionogi &

    • Table Product and Service Introduction of Shionogi &

    • Table Company Profile and Development Status of S.L.A. Pharma

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of S.L.A. Pharma

    • Figure Sales and Growth Rate Analysis of S.L.A. Pharma

    • Figure Revenue and Market Share Analysis of S.L.A. Pharma

    • Table Product and Service Introduction of S.L.A. Pharma

    • Table Company Profile and Development Status of Progenics Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Progenics Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Progenics Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Progenics Pharmaceuticals

    • Table Product and Service Introduction of Progenics Pharmaceuticals

    • Table Company Profile and Development Status of C.B. Fleet Company

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of C.B. Fleet Company

    • Figure Sales and Growth Rate Analysis of C.B. Fleet Company

    • Figure Revenue and Market Share Analysis of C.B. Fleet Company

    • Table Product and Service Introduction of C.B. Fleet Company

    • Table Company Profile and Development Status of Nektar Therapeutics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Nektar Therapeutics

    • Figure Sales and Growth Rate Analysis of Nektar Therapeutics

    • Figure Revenue and Market Share Analysis of Nektar Therapeutics

    • Table Product and Service Introduction of Nektar Therapeutics

    • Table Company Profile and Development Status of Theravance Biopharma

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Theravance Biopharma

    • Figure Sales and Growth Rate Analysis of Theravance Biopharma

    • Figure Revenue and Market Share Analysis of Theravance Biopharma

    • Table Product and Service Introduction of Theravance Biopharma

    • Table Company Profile and Development Status of Ironwood Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Ironwood Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Ironwood Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Ironwood Pharmaceuticals

    • Table Product and Service Introduction of Ironwood Pharmaceuticals

    • Table Company Profile and Development Status of SLA Pharma

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of SLA Pharma

    • Figure Sales and Growth Rate Analysis of SLA Pharma

    • Figure Revenue and Market Share Analysis of SLA Pharma

    • Table Product and Service Introduction of SLA Pharma

    • Table Company Profile and Development Status of Sucampo Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Sucampo Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Sucampo Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Sucampo Pharmaceuticals

    • Table Product and Service Introduction of Sucampo Pharmaceuticals

    • Table Company Profile and Development Status of Daiichi Sankyo Co

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Daiichi Sankyo Co

    • Figure Sales and Growth Rate Analysis of Daiichi Sankyo Co

    • Figure Revenue and Market Share Analysis of Daiichi Sankyo Co

    • Table Product and Service Introduction of Daiichi Sankyo Co

    • Table Company Profile and Development Status of Pfizer

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Pfizer

    • Figure Sales and Growth Rate Analysis of Pfizer

    • Figure Revenue and Market Share Analysis of Pfizer

    • Table Product and Service Introduction of Pfizer

    • Table Company Profile and Development Status of Takeda Pharmaceutical Company Limited

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Takeda Pharmaceutical Company Limited

    • Figure Sales and Growth Rate Analysis of Takeda Pharmaceutical Company Limited

    • Figure Revenue and Market Share Analysis of Takeda Pharmaceutical Company Limited

    • Table Product and Service Introduction of Takeda Pharmaceutical Company Limited

    • Table Company Profile and Development Status of Mundipharma International Limited

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Mundipharma International Limited

    • Figure Sales and Growth Rate Analysis of Mundipharma International Limited

    • Figure Revenue and Market Share Analysis of Mundipharma International Limited

    • Table Product and Service Introduction of Mundipharma International Limited

    • Table Company Profile and Development Status of Purdue Pharma

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Purdue Pharma

    • Figure Sales and Growth Rate Analysis of Purdue Pharma

    • Figure Revenue and Market Share Analysis of Purdue Pharma

    • Table Product and Service Introduction of Purdue Pharma

    • Table Company Profile and Development Status of Valeant Pharmaceuticals International

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Valeant Pharmaceuticals International

    • Figure Sales and Growth Rate Analysis of Valeant Pharmaceuticals International

    • Figure Revenue and Market Share Analysis of Valeant Pharmaceuticals International

    • Table Product and Service Introduction of Valeant Pharmaceuticals International

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US